Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New Study Published in PNAS Confirms Potential Utility of Marillion´s Nanoparticle Technology for Tumor Targeting Agents


Findings in the Prestigious "Proceedings of the National Academy of Sciences" Describe How Natural Nanoparticles Can Be Adapted to Fight Cancer

Marillion Pharmaceuticals, an emerging biotechnology company developing cancer therapeutics, announced that the science underlying its core technology was published in the "Proceedings of the National Academy of Sciences" (PNAS), a peer-reviewed journal. Marillion´s nanoplatform conjugates tumor-homing molecules to naturally occurring nanoparticles responsible for lipid transport throughout the body. The adapted nanoparticles are able to deliver anti-cancer drugs directly into tumor cells. The technology was developed by scientists from the University of Pennsylvania who helped found the company and who are co-authors of the scientific study published in the PNAS.

Marillion´s nanoparticles, called conjugated lipoproteins, are less than 25 nm in diameter, more than 10,000 times smaller than the width of a human hair. Because of their small size they can pass through blood vessel walls to ferry their cargo of anti-cancer drugs to targeted receptors and directly into the cancer cells, leaving the surrounding healthy tissue unaffected.

"We have shown that we can empty these naturally occurring nanoparticles, fill them with chemotherapeutic and imaging agents and then re-route them away from their natural receptors directly to tumor cells," says Gang Zheng, Ph.D., University of Pennsylvania researcher and Marillion co-founder.

There is a great deal of research activity underway attempting to apply nanoparticle technology to cancer therapy. However, many of the nanoparticles currently being developed are synthetic and may themselves prove toxic to the body, precisely because of their ultra-small size and complex interactions with tissues. Marillion intends to avoid these problems by adapting naturally occurring nanoparticles, which are less susceptible to these toxic effects.

Jerry Glickson, Ph.D. also at the University of Pennsylvania and a co-founder of Marillion, added, "As described in the journal, the targeting entity in this study was folic acid, which binds to specific receptors found on certain types of cancers and directs the nanoparticle to the tumor. Other targeting entities can also be attached to guide the nanoparticles to alternate tumors or to the tumor vasculature, where agents can be delivered that fight the cancer by literally starving the tumor of it´s essential blood supply. The particles´ trajectory through the body can also be tracked by attaching imaging agents to the nanoparticle, providing the potential for an innovative ´see and treat´ approach to cancer therapy."

Marillion´s natural nanoparticles have a number of potential advantages. They are completely biodegradable, have a long half-life in the circulation, can be used with numerous types of targeting agents, are capable of delivering a variety of different types of drugs, and are multifunctional, allowing them to be "loaded" with imaging and therapeutic agents both inside and on the surface of the nanoparticle. Marillion is currently using its nanoparticles to carry the widely used chemotherapeutic drug paclitaxel into ovarian tumors, and it plans to initiate clinical trials with its first nanoplatform-based drugs within the next two years.

"Our natural nanoparticles can be designed to act as miniature drug-laden missiles that are small enough to target tumor cells, yet are expected to be devoid of immunogenic and other adverse effects on the body," said Zahed Subhan, Ph.D., J.D., CEO of Marillion. "The results reported in PNAS bode well for the development of our practical nanoparticle-based approach to improving treatment and outcomes for many cancer patients."

The article titled "Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents" initially appeared in the PNAS on-line edition on November 23, 2005. Co-authors Dr. Gang Zheng, assistant professor in the department of radiology and Dr. Jerry Glickson, director of molecular imaging and professor of radiology, biochemistry & biophysics, are both at the University of Pennsylvania.

About Marillion

Marillion Pharmaceuticals is a dynamic pharmaceutical company dedicated to the discovery, development and commercialization of anticancer drugs based on proprietary tumor targeting technologies licensed exclusively from the University of Pennsylvania. The company is building a pipeline of drugs that are designed to selectively target tumor cells so that they are significantly more effective in killing diseased cells and less toxic to healthy tissues than conventional therapies.

Ellen Semple
+1 215.966.6207

Barbara Lindheim
GendeLLindheim BioCom Partners
+1 212.918.4650

| directnews
Further information:

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>